Radiopharmaceutical developer Navidea Biopharmaceuticals has posted lower revenue for its second quarter (end-June 30).
Total revenue for the quarter was $542,000, compared with $612,000 in the second quarter of last year. Revenue for the first six months of 2018 was $819,000, compared with $1.2 million for the same period in 2017.
However, the company's net loss for the quarter decreased to $2.4 million, dropping from $5.2 million in the same quarter of 2017. Its net loss for the six-month period was $9.1 million, compared with net income of $80.4 million in 2017.
